Extrahepatic Y Complication; Gastric Ulcer Secondary to Y Therapy for Liver Metastasis Despite Negative Preprocedural Imaging.

Transarterial radioembolization using yttrium-90 (Y) therapy has become a standard modality of treatment for primary and metastatic liver malignancies due to its high efficacy rate and relatively low risk of adverse effects compared to other forms of locoregional and systemic therapies. Non-target distribution of radio embolic beads and adjacent structure radiation are the two most common adverse effects. However, these are rarely encountered due to thorough imaging and mapping studies prior to Y therapy.